CA2686954A1 - Methods for diagnosing and treating prostate and lung cancer - Google Patents

Methods for diagnosing and treating prostate and lung cancer Download PDF

Info

Publication number
CA2686954A1
CA2686954A1 CA 2686954 CA2686954A CA2686954A1 CA 2686954 A1 CA2686954 A1 CA 2686954A1 CA 2686954 CA2686954 CA 2686954 CA 2686954 A CA2686954 A CA 2686954A CA 2686954 A1 CA2686954 A1 CA 2686954A1
Authority
CA
Canada
Prior art keywords
gpr110
antibody
prostate
sample
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2686954
Other languages
English (en)
French (fr)
Inventor
Bruce Wang
Matthias Wabl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Picobella LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2686954A1 publication Critical patent/CA2686954A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G01N33/5752—
    • G01N33/57555—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA 2686954 2007-05-08 2008-05-08 Methods for diagnosing and treating prostate and lung cancer Abandoned CA2686954A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91671907P 2007-05-08 2007-05-08
US60/916,719 2007-05-08
PCT/US2008/005983 WO2008140774A2 (en) 2007-05-08 2008-05-08 Methods for diagnosing and treating prostate and lung cancer

Publications (1)

Publication Number Publication Date
CA2686954A1 true CA2686954A1 (en) 2008-11-20

Family

ID=40002842

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2686954 Abandoned CA2686954A1 (en) 2007-05-08 2008-05-08 Methods for diagnosing and treating prostate and lung cancer

Country Status (7)

Country Link
US (1) US20130224209A1 (enExample)
EP (1) EP2156184B1 (enExample)
JP (1) JP2010528261A (enExample)
CN (1) CN101918836B (enExample)
AU (1) AU2008251877A1 (enExample)
CA (1) CA2686954A1 (enExample)
WO (1) WO2008140774A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101754812B (zh) 2007-05-04 2013-06-26 克拉洛诊断仪器公司 流体连接器和微流体系统
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
JP2013528622A (ja) * 2010-06-04 2013-07-11 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 炎症性障害の処置
JP5909070B2 (ja) * 2010-10-28 2016-04-26 国立大学法人 東京大学 Ｇｓ共役受容体に対する医薬品候補化合物をスクリーニングする方法
AU2013230167B2 (en) 2012-03-05 2018-05-24 Opko Diagnostics, Llc Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
CN102914658A (zh) * 2012-10-24 2013-02-06 高维强 Crisp3蛋白在前列腺癌诊断和治疗中的应用
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
EP3094976B1 (en) 2014-01-17 2020-03-25 Minomic International Ltd. Cell surface prostate cancer antigen for diagnosis
CN104090103B (zh) * 2014-03-24 2016-08-31 福州市传染病医院 基于抗体修饰ZnSe纳米晶检测肝癌标志物GPC3的试剂盒
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
WO2015148979A1 (en) * 2014-03-28 2015-10-01 Opko Diagnostics, Llc Compositons and methods related to diagnosis of prostate cancer
EP2944652A1 (en) * 2014-05-13 2015-11-18 Technische Universität München Glypican-3-specific T-cell receptors and their uses for immunotherapy of hepatocellular carcinoma
CN114807368A (zh) 2014-07-14 2022-07-29 威拉赛特公司 用于评估肺癌状态的方法
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
WO2016073768A1 (en) 2014-11-05 2016-05-12 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
JP6749337B2 (ja) 2015-03-27 2020-09-02 オプコ・ダイアグノスティクス・リミテッド・ライアビリティ・カンパニーＯｐｋｏ Ｄｉａｇｎｏｓｔｉｃｓ，Ｌｌｃ 前立腺抗原標準およびその使用
CN112034185A (zh) * 2020-09-11 2020-12-04 上海市胸科医院 Gpr110、vegfr、cd34在鉴别肺腺癌亚型中的用途
KR102730255B1 (ko) * 2022-08-12 2024-11-15 (주)맥시온 암 진단용 다중 바이오마커 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2795403B2 (ja) * 1986-07-30 1998-09-10 株式会社 シノテスト 免疫的測定方法及び装置
US6277972B1 (en) * 1998-08-10 2001-08-21 Urogenesys, Inc. BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells
AU2001297556A1 (en) * 2000-11-08 2002-10-03 Millennium Pharmaceuticals, Inc. 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof
JP2005527180A (ja) * 2001-04-18 2005-09-15 プロテイン デザイン ラブス， インコーポレイテッド 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法
AU2002337657A1 (en) * 2001-07-25 2003-02-17 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2004023145A1 (ja) * 2002-09-04 2004-03-18 Perseus Proteomics Inc. Ｇｐｃ3の検出による癌の診断方法
WO2006086578A1 (en) * 2002-10-02 2006-08-17 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Internal biochemical sensing device
JP2004279157A (ja) * 2003-03-14 2004-10-07 Rohto Pharmaceut Co Ltd 癌病巣判定のためのキット並びに方法
US20060094046A1 (en) * 2004-02-11 2006-05-04 Arie Abo Compositions and methods relating to angiogenesis and tumorigenesis
WO2005085292A2 (fr) * 2004-03-03 2005-09-15 Biomerieux Procede de detection de la forme libre activable du psa et son utilisation pour le diagnostic des pathologies benignes de la prostate et de l'adenocarcinome de la prostate
US20060252057A1 (en) * 2004-11-30 2006-11-09 Mitch Raponi Lung cancer prognostics
US20060211059A1 (en) * 2005-03-18 2006-09-21 Taneja Samir S Methods of improving screening, diagnosis and staging of prostate cancer using serum testosterone
JP2007075072A (ja) * 2005-09-16 2007-03-29 Satoshi Takahashi プロサイモシンαの機能抑制用組成物を含む抗癌剤、およびプロサイモシンα遺伝子の発現抑制用組成物に含有される核酸
WO2007047796A2 (en) * 2005-10-17 2007-04-26 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use

Also Published As

Publication number Publication date
AU2008251877A1 (en) 2008-11-20
WO2008140774A9 (en) 2010-02-11
US20130224209A1 (en) 2013-08-29
CN101918836A (zh) 2010-12-15
EP2156184A4 (en) 2010-07-21
JP2010528261A (ja) 2010-08-19
EP2156184B1 (en) 2013-11-27
WO2008140774A2 (en) 2008-11-20
EP2156184A2 (en) 2010-02-24
AU2008251877A2 (en) 2010-02-04
CN101918836B (zh) 2014-04-30
AU2008251877A9 (en) 2010-01-21
WO2008140774A3 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
US20130224209A1 (en) Methods for diagnosing and treating prostate and lung cancer
US8071324B2 (en) Methods for diagnosing and treating kidney cancer
US20100041126A1 (en) Methods for diagnosing and treating prostate cancer
US20090258358A1 (en) Methods for Diagnosing and Treating Kidney and Colorectal Cancer
AU2011250588C1 (en) Method for the diagnosis of epithelial cancers by the detection of EpICD polypeptide
KR100819395B1 (ko) 포유류에서의 전-종양 및/또는 종양 상태의 확인법
US9625461B2 (en) Method of detecting cancer using delta-catenin
CA2662012C (en) Boris isoforms and methods of detecting and treating disease
US7910316B2 (en) Kit and method for detecting urothelial cancer
WO2003097872A2 (en) G - protein coupled receptor marker molecules associated with colorectal lesions
US20080095805A1 (en) Method Of Detecting Cancer Based On Immune Reaction To Boris
WO2002016939A2 (en) Methods of diagnosis of cancer and screening for cancer modulators
JP2009195243A (ja) Ｔｂｘ２１の変更された発現に関連する癌における新規組成物および方法
JP2009168669A (ja) 胃癌の診断又は検出のための組成物及び方法
KR101219979B1 (ko) 갑상선 유두암종의 림프절 전이 진단 방법
JP3524536B2 (ja) 癌の診断、モニタリング、ステージング、イメージングおよび処置のための新規方法
JP2004511758A (ja) 大腸癌の診断、モニタリング、ステージング、イメージングおよび処置の方法
US6379893B1 (en) Evaluation of adenocarcinoma of the prostate and breast using anti-dystroglycan antibodies
US20030087245A1 (en) Uses of PBH1 in the diagnosis and therapeutic treatment of prostate cancer
US8313917B2 (en) Methods of diagnosing latent and active malignancies
JP2008263840A (ja) 胃ガンの診断又は検出のための組成物及び方法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140508

FZDE Discontinued

Effective date: 20140508